Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders

Figure 2

The molecular targets for cardiopulmonary-associated drugs. Recetoromic screening revealed the molecular targets implicated in fenfluramine. 5-HT2B serotonin receptor was identified as a molecular target for the norfenfluramine (a metabolite of fenfluramine), methylergonovine (a metabolite of the valvular heart disease- and pulmonary hypertension-associated drug methysergide), and dihydroergotamine (potentially associated with valvular heart disease and pulmonary hypertension). The drugs associated with cardio diseases also show high affinity to α-2B adrenergic receptors, whereas fluoxetine and the metabolite norfluoxetine do not. In this heat map, the affinity of the drugs is mapped by color gradient, that is, blue (lower affinity, higher Ki), red (higher affinity, lower Ki), and intermediated color (reprinted with permission from Nature Publishing Group).